Ignite Creation Date:
2024-05-05 @ 6:45 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00542308
Status:
COMPLETED
Last Update Posted:
2023-08-03
First Post:
2007-10-10
Brief Title:
Zalutumumab in Non-curable Patients With SCCHN
Sponsor:
Genmab
Organization:
Genmab
Study Overview
Official Title:
An Open Label Single Arm Trial Investigating Zalutumumab a Human Monoclonal Anti-EGF Receptor Antibody in Combination With Best Supportive Care in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment In combination with BSC Open-label Single arm Efficacy Study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None